QQQ   427.15 (+0.31%)
AAPL   167.87 (-0.08%)
MSFT   411.27 (-0.14%)
META   508.27 (+2.85%)
GOOGL   155.97 (+0.32%)
AMZN   181.94 (+0.36%)
TSLA   150.30 (-3.31%)
NVDA   857.25 (+2.01%)
AMD   156.12 (+1.36%)
NIO   4.04 (+3.32%)
BABA   69.37 (+0.80%)
T   16.19 (+0.43%)
F   12.14 (+0.83%)
MU   113.67 (-2.29%)
GE   156.52 (+0.55%)
CGC   7.84 (+20.80%)
DIS   113.60 (+0.58%)
AMC   2.92 (-2.01%)
PFE   25.37 (-0.20%)
PYPL   62.69 (-0.90%)
XOM   118.74 (+0.09%)
QQQ   427.15 (+0.31%)
AAPL   167.87 (-0.08%)
MSFT   411.27 (-0.14%)
META   508.27 (+2.85%)
GOOGL   155.97 (+0.32%)
AMZN   181.94 (+0.36%)
TSLA   150.30 (-3.31%)
NVDA   857.25 (+2.01%)
AMD   156.12 (+1.36%)
NIO   4.04 (+3.32%)
BABA   69.37 (+0.80%)
T   16.19 (+0.43%)
F   12.14 (+0.83%)
MU   113.67 (-2.29%)
GE   156.52 (+0.55%)
CGC   7.84 (+20.80%)
DIS   113.60 (+0.58%)
AMC   2.92 (-2.01%)
PFE   25.37 (-0.20%)
PYPL   62.69 (-0.90%)
XOM   118.74 (+0.09%)
QQQ   427.15 (+0.31%)
AAPL   167.87 (-0.08%)
MSFT   411.27 (-0.14%)
META   508.27 (+2.85%)
GOOGL   155.97 (+0.32%)
AMZN   181.94 (+0.36%)
TSLA   150.30 (-3.31%)
NVDA   857.25 (+2.01%)
AMD   156.12 (+1.36%)
NIO   4.04 (+3.32%)
BABA   69.37 (+0.80%)
T   16.19 (+0.43%)
F   12.14 (+0.83%)
MU   113.67 (-2.29%)
GE   156.52 (+0.55%)
CGC   7.84 (+20.80%)
DIS   113.60 (+0.58%)
AMC   2.92 (-2.01%)
PFE   25.37 (-0.20%)
PYPL   62.69 (-0.90%)
XOM   118.74 (+0.09%)
QQQ   427.15 (+0.31%)
AAPL   167.87 (-0.08%)
MSFT   411.27 (-0.14%)
META   508.27 (+2.85%)
GOOGL   155.97 (+0.32%)
AMZN   181.94 (+0.36%)
TSLA   150.30 (-3.31%)
NVDA   857.25 (+2.01%)
AMD   156.12 (+1.36%)
NIO   4.04 (+3.32%)
BABA   69.37 (+0.80%)
T   16.19 (+0.43%)
F   12.14 (+0.83%)
MU   113.67 (-2.29%)
GE   156.52 (+0.55%)
CGC   7.84 (+20.80%)
DIS   113.60 (+0.58%)
AMC   2.92 (-2.01%)
PFE   25.37 (-0.20%)
PYPL   62.69 (-0.90%)
XOM   118.74 (+0.09%)
Free Trial
NASDAQ:SBTX

Silverback Therapeutics (SBTX) Stock Price, News & Analysis

→ A.I. Pioneer Issues Urgent Warning to Americans (From TradeSmith) (Ad)
Free SBTX Stock Alerts
$9.06
-0.12 (-1.31%)
(As of 04/17/2024 ET)
Compare
Today's Range
$8.88
▼
$9.28
50-Day Range
$6.30
▼
$10.22
52-Week Range
$2.80
▼
$8.97
Volume
456,563 shs
Average Volume
337,931 shs
Market Capitalization
$326.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsFinancialsInsider TradesOwnershipSEC FilingsSocial Media
SBTX stock logo

About Silverback Therapeutics Stock (NASDAQ:SBTX)

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

SBTX Stock Price History

SBTX Stock News Headlines

May 11, 2023 | uk.investing.com
ARS Pharmaceuticals Inc (SPRY)
January 24, 2023 | seekingalpha.com
SPRY ARS Pharmaceuticals, Inc.
April 18, 2024 | TradeSmith (Ad)
A.I. Pioneer Issues Urgent Warning to Americans
According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”
November 22, 2022 | 247wallst.com
ARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After Merger
November 18, 2022 | nasdaq.com
Dr. Sarina Tanimoto Discloses Position in SBTX / Silverback Therapeutics
November 10, 2022 | finance.yahoo.com
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
November 8, 2022 | finance.yahoo.com
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
October 28, 2022 | markets.businessinsider.com
Silverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic Reactions
April 18, 2024 | TradeSmith (Ad)
A.I. Pioneer Issues Urgent Warning to Americans
According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”
October 21, 2022 | finance.yahoo.com
Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis
September 17, 2022 | markets.businessinsider.com
INVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBT
September 15, 2022 | seekingalpha.com
SBTX Silverback Therapeutics, Inc.
September 6, 2022 | markets.businessinsider.com
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBT
August 23, 2022 | markets.businessinsider.com
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZY
August 17, 2022 | apnews.com
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VIVO, HNGR, SBTX
August 11, 2022 | apnews.com
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates IEA, BBQ, SBTX
July 30, 2022 | morningstar.com
SHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing Investigations
July 28, 2022 | apnews.com
INVESTIGATION ALERT: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZY
July 27, 2022 | benzinga.com
Shareholder Alert - The M&A Class Action Firm Announces the Investigation of Silverback Therapeutics, Inc. - SBTX
July 26, 2022 | apnews.com
Lifshitz Law PLLC Announces Investigation of IEA, ZY, SBTX, and HNGR
July 26, 2022 | finance.yahoo.com
Silverback Therapeutics plans merger with San Diego biotech
July 25, 2022 | apnews.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates HNGR, SBTX, U
July 22, 2022 | benzinga.com
SILVERBACK THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of SBTX and Encourages Investors to Contact the Firm
July 22, 2022 | prnewswire.com
SHAREHOLDER ALERT: Weiss Law Investigates Silverback Therapeutics, Inc.
July 22, 2022 | apnews.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates HNGR, ONEM, SBTX, ZEN
July 22, 2022 | finance.yahoo.com
Once A Cancer Company, Silverback Merges With Small Biotech Working On Allergy Treatment
July 22, 2022 | marketwatch.com
Silverback Therapeutics Shares Down After Merger News
See More Headlines
Receive SBTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silverback Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
4/18/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SBTX
CUSIP
N/A
CIK
1671858
Web
www.silverbacktx.com
Phone
206 456 2900
Fax
N/A
Employees
83
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($2.42)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-89,480,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-29.62%
Return on Assets
-28.20%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
67.87
Quick Ratio
67.87

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.41 per share
Price / Book
1.22

Miscellaneous

Outstanding Shares
36,058,000
Free Float
23,654,000
Market Cap
$326.69 million
Optionable
Not Optionable
Beta
0.60
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Dr. Peter A. Thompson FACP (Age 62)
    M.D., Co-Founder & Chairman of Directors
    Comp: $5.12k
  • Mr. Jeffrey C. Pepe J.D.
    Ph.D., Interim CEO, Gen. Counsel & Corp. Sec.
  • Mr. Russ Hawkinson (Age 63)
    Sr. VP of Fin., Interim CFO, Principal Financial Officer & Principal Accounting Officer
  • Mr. Miguel Arcinas M.B.A.
    VP of Corp. Devel. & Investor Relations
  • Jen More
    Director of HR
  • Ms. Sue Hamke
    Sr. VP of Clinical Operations
  • Mr. Dario Gobunquin CPA
    Sr. Director of Accounting & Controller

Key Competitors

View All Competitors

SBTX Stock Analysis - Frequently Asked Questions

How have SBTX shares performed in 2024?

Silverback Therapeutics' stock was trading at $5.48 at the beginning of 2024. Since then, SBTX stock has increased by 65.3% and is now trading at $9.06.
View the best growth stocks for 2024 here.

How were Silverback Therapeutics' earnings last quarter?

Silverback Therapeutics, Inc. (NASDAQ:SBTX) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.65) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.65).

When did Silverback Therapeutics IPO?

Silverback Therapeutics (SBTX) raised $126 million in an initial public offering (IPO) on Friday, December 4th 2020. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs, SVB Leerink and Stifel acted as the underwriters for the IPO and H.C. Wainwright was co-manager.

How do I buy shares of Silverback Therapeutics?

Shares of SBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SBTX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
He Is Giving Away Bitcoin
Crypto Swap Profits
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Could Bitcoin Literally FORCE This Crypto To Rocket Up?
Paradigm Press
Top 5 AI Stocks to Buy for 2024
Market Moving Trends